Pulmonary fibrosis (PF) is a serious and progressive lung disease which is possibly life-
threatening. It causes lung scarring and affects lung functions including epithelial cell injury …

Highlights•Biopharmaceuticals are complex products gaining importance over small
molecules.•They are highly sensitive and selective with potent therapeutic efficacy.•The …

Acute lung injury (ALI) is a frequent and serious complication of sepsis with limited
therapeutic options. Gaining insights into the inflammatory dysregulation that causes sepsis …

Recombinant human deoxyribonuclease I (rhDNase, Pulmozyme®) is the most frequently
used mucolytic agent for the symptomatic treatment of cystic fibrosis (CF) lung disease …

Severe airway inflammatory disorders impose a significant societal burden, and the
available treatments are unsatisfactory. High levels of neutrophil extracellular trap (NET) and …

Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic interstitial lung disease with
unclear etiology and increasing prevalence. Pulmonary administration can make the drug …

The drying of biomolecules into powdered formulations has become the main form of long-
term product stabilisation, allowing for the delivery of safe and efficient medicines. Stability of …

Compared to parenteral administration of colistin, its direct pulmonary administration can
maximize lung drug deposition while reducing systemic adverse side effects and derived …

Drug delivery systems such as liposomes are widely used to stabilize and increase the
plasma half-life of therapeutics. In this article, we have investigated two strategies to …

The therapeutic outcomes of patients with eosinophilic chronic rhinosinusitis (ECRS) remain
unsatisfactory, largely because the underlying mechanisms of eosinophilic inflammation are …